INS and obesity disorder: Manufacturing cost estimates for some GLP1As (semaglutide and liraglutide) were recently published in the context of obesity treatment.15 This study develops methods for estimating pharmaceutical manufacturing costs, updates cost analyses for insulins,12 and provides, to our knowledge, the first published manufacturing cost estimates for SGLT2Is and GLP1As for the treatment of diabetes.